Pcos Risk Calculator
Assess PCOS risk from symptoms, lab values, and Rotterdam diagnostic criteria. Enter values for instant results with step-by-step formulas.
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist
Medical disclaimer: This calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are general estimates and may not reflect your individual circumstances. Always consult a qualified healthcare professional before making decisions about your health.
Pcos Risk Calculator
Calculator
Adjust values & calculateEnter your values below. Every result is computed in your browser — no data is sent to any server.
Formula: Rotterdam Diagnosis = 2 of 3 criteria (Oligo/anovulation + Hyperandrogenism + Polycystic Ovaries)
Worked example — Phenotype A (Classic PCOS) | 3/3 Rotterdam criteria | Risk Score: 75 (Very High Risk)
Formula
Rotterdam Diagnosis = 2 of 3 criteria (Oligo/anovulation + Hyperandrogenism + Polycystic Ovaries)
PCOS diagnosis requires meeting at least 2 of 3 Rotterdam criteria after excluding other causes. The risk score weights each symptom and finding by its diagnostic significance. Phenotype classification (A through D) depends on which specific criteria are met and determines metabolic risk profile.
Worked Examples
Example 1: Classic PCOS Presentation
Problem:A 28-year-old woman has irregular periods every 45-60 days, moderate facial hair growth, persistent acne, BMI of 31, and ultrasound showing polycystic ovaries. Testosterone is elevated.
Solution:Rotterdam criteria assessment: 1. Oligo-ovulation: YES (irregular periods every 45-60 days) 2. Hyperandrogenism: YES (clinical: hirsutism + acne; biochemical: elevated testosterone) 3. Polycystic ovaries: YES (confirmed on ultrasound) All 3 criteria met = Phenotype A (Classic PCOS - Full) Risk score: irregular periods (15) + hirsutism (12) + acne (8) + PCO (15) + elevated T (15) + BMI 30+ (10) = 75 Metabolic risks: Elevated BMI, likely insulin resistance
Result:Phenotype A (Classic PCOS) | 3/3 Rotterdam criteria | Risk Score: 75 (Very High Risk)
Example 2: Mild PCOS Variant
Problem:A 24-year-old with regular periods, mild acne, and polycystic ovaries on ultrasound. Normal BMI of 22, normal testosterone, no hirsutism.
Solution:Rotterdam criteria assessment: 1. Oligo-ovulation: NO (regular periods) 2. Hyperandrogenism: YES (clinical: acne present, though mild) 3. Polycystic ovaries: YES (confirmed on ultrasound) 2 of 3 criteria met = Phenotype C (Ovulatory PCOS) Risk score: acne (8) + PCO (15) = 23 Metabolic risks: Minimal - normal BMI, no insulin resistance markers This is the mildest phenotype with lowest metabolic risk
Result:Phenotype C (Ovulatory PCOS) | 2/3 Rotterdam criteria | Risk Score: 23 (Moderate Risk)
Frequently Asked Questions
What is PCOS and how common is it among women of reproductive age?
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, with prevalence estimates ranging from 6 to 20 percent depending on the diagnostic criteria used. It is characterized by a combination of hormonal imbalances, metabolic dysfunction, and reproductive irregularities. PCOS results from excess androgen production by the ovaries and adrenal glands, often accompanied by insulin resistance that further stimulates androgen production. The condition is not simply about having cysts on the ovaries, as the name misleadingly suggests, but rather involves a complex interplay of genetic, hormonal, and environmental factors. PCOS is the leading cause of anovulatory infertility and significantly increases the risk of type 2 diabetes, cardiovascular disease, and endometrial cancer if left unmanaged.
What are the Rotterdam criteria for diagnosing PCOS?
The Rotterdam criteria, established in 2003 by the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine, require that two of three criteria be present for a PCOS diagnosis after excluding other conditions. The three criteria are: oligo-ovulation or anovulation (irregular or absent menstrual cycles), clinical or biochemical signs of hyperandrogenism (excess male hormones manifesting as acne, hirsutism, hair loss, or elevated testosterone levels), and polycystic ovarian morphology on ultrasound (12 or more follicles measuring 2 to 9 mm in diameter, or an ovarian volume exceeding 10 mL). This system replaced the earlier NIH criteria that required both irregular periods and hyperandrogenism. The Rotterdam criteria identify four distinct phenotypes, with Phenotype A being the most metabolically severe and Phenotype D being the mildest.
How does insulin resistance contribute to PCOS development?
Insulin resistance plays a central role in PCOS pathophysiology for approximately 70 to 80 percent of affected women. When cells become resistant to insulin, the pancreas compensates by producing more insulin (hyperinsulinemia). Elevated insulin directly stimulates ovarian theca cells to produce excess androgens and reduces the liver production of sex hormone-binding globulin (SHBG), which increases free testosterone levels. High insulin also impairs normal follicular development, leading to anovulation and the accumulation of small antral follicles that give the ovaries their polycystic appearance. Insulin resistance in PCOS appears to involve a post-receptor signaling defect specific to the metabolic pathway while the mitogenic pathway remains intact, creating a unique form of selective insulin resistance. This is why weight management and insulin-sensitizing medications like metformin are often first-line treatments for PCOS.
What are the different PCOS phenotypes and why do they matter?
PCOS is classified into four phenotypes based on which Rotterdam criteria are present, and each carries different metabolic and reproductive risk profiles. Phenotype A (classic PCOS) meets all three criteria and carries the highest risk of metabolic complications including insulin resistance, dyslipidemia, and type 2 diabetes. Phenotype B (non-polycystic ovary PCOS) has irregular periods and hyperandrogenism without polycystic ovaries and carries similar metabolic risk to Phenotype A. Phenotype C (ovulatory PCOS) has hyperandrogenism and polycystic ovaries but regular cycles, with moderate metabolic risk. Phenotype D (non-hyperandrogenic PCOS) has irregular periods and polycystic ovaries without androgen excess and carries the lowest metabolic risk. Understanding phenotype helps clinicians tailor treatment approaches and counseling about long-term health risks.
What blood tests are used to evaluate suspected PCOS?
A comprehensive PCOS workup includes several blood tests to confirm diagnosis and rule out other conditions. Total and free testosterone levels assess biochemical hyperandrogenism, with free testosterone being more sensitive. DHEA-S (dehydroepiandrosterone sulfate) evaluates adrenal androgen production. 17-hydroxyprogesterone screens for non-classic congenital adrenal hyperplasia, which can mimic PCOS. Thyroid function tests (TSH and free T4) rule out thyroid disorders that can cause menstrual irregularity. Prolactin levels exclude hyperprolactinemia. Fasting glucose and insulin levels or an oral glucose tolerance test assess insulin resistance. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio is often elevated in PCOS, typically above 2:1. Anti-Mullerian hormone (AMH) is often elevated and correlates with antral follicle count. A lipid panel evaluates cardiovascular risk factors commonly altered in PCOS.
How does PCOS affect fertility and what treatments are available?
PCOS is the most common cause of anovulatory infertility, accounting for approximately 80 percent of cases. The hormonal imbalances prevent regular ovulation, making conception difficult but not impossible. Many women with PCOS can conceive with appropriate treatment. First-line ovulation induction treatment is letrozole (an aromatase inhibitor), which has replaced clomiphene citrate as the preferred option based on evidence of higher live birth rates. Weight loss of even 5 to 10 percent of body weight can restore ovulation in overweight women with PCOS. Metformin may improve ovulation rates when combined with lifestyle modifications. Gonadotropin injections are second-line treatment for women who do not respond to oral medications. In vitro fertilization (IVF) is reserved for cases refractory to other treatments. Women with PCOS undergoing IVF have a higher risk of ovarian hyperstimulation syndrome and require careful monitoring and modified protocols.
What lifestyle modifications are most effective for managing PCOS?
Lifestyle modification is considered the first-line treatment for PCOS, particularly in overweight individuals. A calorie-controlled diet emphasizing low glycemic index foods, adequate protein (1.2 to 1.6 grams per kilogram per day), and anti-inflammatory foods has been shown to reduce androgen levels and improve insulin sensitivity within 3 to 6 months. Regular exercise combining both aerobic activity (150 minutes per week) and resistance training (2 to 3 sessions per week) improves insulin sensitivity independently of weight loss. Weight loss of 5 to 10 percent significantly reduces testosterone levels, improves menstrual regularity, and restores ovulation in many cases. Stress management through mindfulness, yoga, or cognitive behavioral therapy addresses the cortisol elevation common in PCOS. Sleep optimization is important because sleep deprivation worsens insulin resistance. Reducing exposure to endocrine-disrupting chemicals in plastics and personal care products may also provide benefit.
What are the long-term health risks associated with PCOS?
PCOS significantly increases the risk of several chronic conditions throughout a woman's lifetime. Type 2 diabetes risk is 4 to 7 times higher in women with PCOS, and up to 40 percent develop prediabetes or diabetes by age 40. Cardiovascular disease risk is elevated due to dyslipidemia, hypertension, chronic inflammation, and endothelial dysfunction associated with PCOS. Endometrial cancer risk is 2.7 times higher because chronic anovulation results in unopposed estrogen stimulation of the uterine lining. Obstructive sleep apnea is 5 to 30 times more common in women with PCOS, partly due to androgen effects on upper airway muscles. Non-alcoholic fatty liver disease affects up to 40 percent of women with PCOS. Depression and anxiety are 3 to 4 times more prevalent, likely related to both hormonal factors and the psychological impact of symptoms like hirsutism and infertility. Regular screening and proactive management of these comorbidities is essential for long-term health.
Can PCOS symptoms change or improve with age?
PCOS symptoms do evolve over a woman's lifetime, though the condition itself does not fully resolve. Androgen levels gradually decline with age, which means symptoms like acne and hirsutism may improve during the late 30s and 40s. Menstrual cycles often become more regular as women approach menopause because the hormonal fluctuations that characterize perimenopause can paradoxically normalize cycle patterns in some women with PCOS. However, metabolic aspects of PCOS typically worsen with age as insulin resistance increases and weight management becomes more challenging. The cardiovascular risk associated with PCOS persists and may accelerate after menopause when the protective effects of estrogen decline. Women with PCOS tend to have later menopause onset (by 1 to 2 years) due to larger ovarian follicle reserves. Continued monitoring of metabolic markers, cardiovascular risk factors, and endometrial health remains important throughout life regardless of symptom improvement.
How does family history influence PCOS risk and what genetic factors are involved?
PCOS has a strong genetic component, with first-degree relatives of affected women having a 40 to 50 percent chance of developing the condition. Twin studies show heritability estimates of 70 to 80 percent. However, PCOS is a polygenic disorder, meaning no single gene causes it but rather multiple genetic variants each contribute a small amount of risk. Genome-wide association studies have identified susceptibility loci related to androgen biosynthesis, insulin signaling, gonadotropin regulation, and inflammation. Daughters of women with PCOS may show elevated AMH levels and altered ovarian morphology even before puberty, suggesting prenatal androgen exposure contributes to programming the condition. Brothers and fathers of women with PCOS have higher rates of metabolic syndrome, insulin resistance, and premature balding, indicating that the genetic susceptibility affects both sexes. Environmental factors including diet, physical activity, stress, and endocrine disruptor exposure interact with genetic predisposition to determine whether and how severely PCOS manifests.
References
Reviewed for accuracy by Rahul Singh, Health & Wellness Specialist · Editorial policy
Related Calculators
🧮Framingham Risk Calculator
Calculate framingham risk with inputs, formulas, and instant results.
🧮Gupta Risk Calculator
Calculate gupta risk with inputs, formulas, and instant results.
🧮Perioperative Cardiac Risk Calculator
Calculate perioperative cardiac risk with inputs, formulas, and instant results.
🧮Diabetes Risk Calculator
Calculate diabetes risk with inputs, formulas, and instant results.
🧮Hypoglycemia Risk Calculator
Calculate hypoglycemia risk with inputs, formulas, and instant results.
🧮Diet Risk Score Calculator
Calculate diet risk score with inputs, formulas, and instant results.
🧮Breast Cancer Recurrence Risk Calculator
Calculate breast cancer recurrence risk with inputs, formulas, and instant results.
🧮Breast Cancer Risk Calculator
Calculate breast cancer risk with inputs, formulas, and instant results.